New ‘pulsing’ ultrasound technique improves drug delivery to brains of mice
Imperial launches one of world's first online Masters in Machine Learning
New European collaborations supported by Imperial seed fund
CDDS researchers work across a wide range of diseases, from infection and inflammation to oncology, cardiovascular disease and neurodegeneration.
View our network of disease experts
The CDDS brings together expertise in new screening technologies, target deconvolution, ultrasensitive biomarker analysis, microfluidic devices, and more.
View technology areas
We are developing small molecule, peptide, biological and cell-based modalities across a wide range of target classes and novel modes of action.
View target classes